業績（論文）

　Psoas muscle index as an independent prognostic factor in patients with unresectable pancreatic cancer: A retrospective analysis.

Hirosaki Medical Journal. 76(1-4): 82-93, 2026.

　Yu Chen, Soichiro Tatsuo, Tomohiro Shintaku, Kensuke Saito, Shingo Kakeda, Atsushi Sato

RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research. Targeted Oncology.

DOI：10.1038/s41598-026-42033-w, 2026.

Shonosuke Wakayama, Shin Takahashi, Kota Ouchi, Yasuhiro Sakamoto, Tadamichi Denda, Atsuo Takashima, Yoshito Komatsu, Masato Nakamura, Hisatsugu Ohori, Tatsuro Yamaguchi, Yoshimitsu Kobayashi, Hideo Baba, Masanori Kotake, Kenji Amagai, Hitoshi Kondo, Ken Shimada, Yasuhide Yamada, Atsushi Sato, Satoshi Yuki, Akira Okita, Keigo Komine, Mika Watanabe, Satoshi Morita, Chikashi Ishioka

Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201) .

Support Care Cancer. 34(3): 221. doi: 10.1007/s00520-026-10445-z.

Kazuaki Harada, Shinya Kajiura, Kentaro Sawada, Kazuteru Hatanaka, Atsushi Sato, Ken Ito, Hotaka Tamura, Ayako Doi, Takayuki Ando, Michio Nakamura, Hiroshi Nakatsumi, Tetsuhito Muranaka, Susumu Sogabe, Takahiro Ishii, Shintaro Nakano, Masayoshi Dazai, Yusuke Sasaki, Yasuyuki Kawamoto, Satoshi Yuki, Yuh Sakata & Yoshito Komatsu

JPOS/JASCC clinical guidelines for psychological distress in adult cancer patients: a summary of recommendations.

Int J Clin Oncol. 56(3):324-336, 2026.

Daisuke Fujisawa, Eisho Yoshikawa, Maiko Fujimori, Sachiko Arai, Makoto Kobayakawa, Akiko Kurata, Ayako Kayano, Kanako Ichikura, Yuri Igarashi, Hiroyuki Otani, Yuko Yanai, Tomoko Baba, Yoshiro Okajima, Akiko Abe, Yu Uneno, Masako Okamura, Yoshihisa Matsumoto, Kurumi Asaumi, Kazuho Hisamura, Kanae Momino, Emi Takeuchi, Atsushi Sato, Noriko Tamura, Akiko Imai, Ryoichi Sadahiro, Toru Okuyama

Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology

Int J Clin Oncol. 2024 Jun;29(6):700-705. doi: 10.1007/s10147-024-02541-z.

Kenji Tsuchihashi, Mamoru Ito, Yuta Okumura, Kenta Nio, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Eishi Baba

Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022

Int J Clin Oncol. 2024 Aug;29(8):1074-1080. doi: 10.1007/s10147-024-02570-8.

Kazuki Nozawa, Yukinori Ozaki, Tetsuhiro Yoshinami, Takamichi Yokoe, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito 6, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology

Int J Clin Oncol. 2024 Aug;29(8):1081-1087. doi: 10.1007/s10147-024-02572-6.

Takeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Makoto Endo

　Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology

　Int J Clin Oncol. 2024 Aug;29(8):1067-1073. doi: 10.1007/s10147-024-02569-1.

　Takeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Makoto Endo

Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

Int J Clin Oncol. 2024 May;29(5):551-558. doi: 10.1007/s10147-024-02499-y.

Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

Efficacy and safety of dose‑dense chemotherapy for early‑stage breast cancer under prophylactic pegfilgrastim administration: a systematic

review and meta‑analysis from clinical practice guidelines for the use of G‑CSF 2022

Int J Clin Oncol. 2025 Feb 12. doi: 10.1007/s10147-025-02716-2.

Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma , Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study. Gastric Cancer 2023 Nov 26 (6): 1020-1029. doi: 10.1007/s10120-023-01423-z.

Ryo Kawabata, Kunihiro Chin, Daisuke Takahari, Hiroshi Hosaka, Osamu Muto, Yoshiaki Shindo, Hirofumi Nagata, Hiroshi Yabusaki, Hiroshi Imamura, Shinichi Endo, Tadamichi Kashiwada, Masato Nakamura, Junichi Hihara, Mitsuo Kobayashi, Takeshi Sagawa, Sho Saito, Atsushi Sato, Tomoko Yamada, Naotoshi Okano, Naoki Shimada, Masashi Matsushima, Masayuki Kataoka, Shinichi Matsumoto, Masahiro Goto, Masahito Kotaka, Toshiro Shiraishi, Hirotoshi Yamai, Fumihiro Nagashima, Isao Ishizuka, Kuniaki Yamaguchi　

Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy. Cancer Chemother Pharmacol 92 (5): 391-398, 2023.

Junichi Nakagawa, Takenori Takahata, Yu Chen, Keigo Saito, Kosuke Kamata, Takuto Tachita, Satoru Yamashita, Kensuke Saito, Kayo Ueno, Atsushi Sato, Hirotake Sakuraba, Takenori Niioka

Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201). BMC Cancer 2024 Feb 24; 24 (1): 262. doi: 10.1186/s12885-024-11973-9.

Hitoshi Imai, Yoshiaki Sakamoto, Shin Takahashi, Hiroyuki Shibata, Atsushi Sato, Kazunori Otsuka, Kenji Amagai, Masanobu Takahashi, Tatsuro Yamaguchi, Chikashi Ishioka

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022. Int J Clin Oncol. 2024 Feb 14. doi: 10.1007/s10147-024-02469-4.

Gaku Makimoto, Katsuyuki Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Nobuaki Ochi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Toshio Kubo

Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022. Int J Clin Oncol. 2024 Mar 22. doi: 10.1007/s10147-024-02491-6.

Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Toshiaki Maeda, Yasufumi Najima, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Shingo Yano

Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology. Int J Clin Oncol. 2024 Mar 18. doi: 10.1007/s10147-023-02465-0.

Keita Uchino, Shinobu Tamura, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Shinya Kimura, Kenji Shigeta, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Yuji Miura

Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022. Int J Clin Oncol. 2024 Mar 25. doi: 10.1007/s10147-024-02499-y.

Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Mamoru Ito, Eishi Baba, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer

Shintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, Kazuaki Harada, Takuto Miyagishima, Susumu Sogabe, Masayoshi Dazai, Atsushi Sato, Atsushi Ishiguro, Michio Nakamura, Shinya Kajiura, Yasuo Takahashi, Miki Tateyama, Kazuteru Hatanaka, Yasushi Tsuji, Takahide Sasaki, Yoshiaki Shindo, Tomoe Kobayashi, Isao Yokota, Naoya Sakamoto, Yuh Sakata, Yoshito Komatsu

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report

Kota Sasaki 1 2, Yusuke Yokota 2, Toshihito Isojima 2, Mayumi Fujii 3, Kengo Hasui 1, Yu Chen 1, Kensuke Saito 1, Takenori Takahata 1, Seiko Kindaichi 3, Atsushi Sato 1

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)

Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, Kazuteru Hatanaka, Minoru Uebayashi, Michio Nakamura, Hiroyuki Okuda, Ichiro Iwanaga, Takashi Kato, Shintaro Nakano, Atsushi Sato, Kazuaki Harada, Koji Oba, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.

Denda T, Takashima A, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Nakamura M, Ohori H, Sakashita A, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Yamada Y, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T, Shimada K

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.

Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C